King-Friend Biochemical Pharma advances share repurchase program

Nanjing King-Friend Biochemical Pharmaceutical (King-Friend Biochemical Pharma) announced progress on its share repurchase program, initiated on April 29, 2025, following a proposal by chairman Tang Yongqun. Approved by the board on April 28, 2025, and shareholders on May 20, 2025, the program aims to repurchase shares for employee stock ownership plans or equity incentives within 12 months.

As of November 30, 2025, King-Friend Biochemical Pharma has cumulatively repurchased 1,379,995 shares through the Shanghai Stock Exchange trading system. This represents 0.09% of the company's total share capital. Repurchases were made at prices ranging from RMB 9.56 to RMB 11.66 per share, totaling RMB 15,008,500, excluding transaction fees and stamp duty. The company's repurchase plan targets an investment between RMB 20,000,000 and RMB 40,000,000, with a maximum repurchase price of RMB 18.75 per share.

King-Friend Biochemical Pharma stated its commitment to adhering to relevant regulations and will continue to make timely disclosures on the program's progress. The company advises investors to be aware of potential investment risks.